리가켐바이오, ADC 항암 후보물질 임상시험 FDA 승인 신청

LigaChem Bio's FDA application for LCB02A marks a significant step in the competitive ADC market, specifically targeting the CLDN18.2 protein found in solid tumors. This clinical trial highlights the growing global interest in high-precision cancer therapies and the increasing capability of Korean biotech firms to pursue international regulatory approvals for next-generation treatments.